Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Dec 1 (Reuters) - Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound ...

This is the second time the company has cut down prices of Zepbound on LillyDirect. Eli Lilly said it was making the weight loss drug more accessible to people suffering from obesity.

Eli Lilly is cutting what self-paying patients shell out for its blockbuster obesity drug Zepbound when they buy single-dose ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.

Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, ...

Lilly lowers the price of its obesity drug Zepbound to make it more affordable for U.S. patients. Surging demand propels ...

Calls have been more popular than usual in the options pits. LLY's 50-day call/put volume ratio of 2.23 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.